Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

by Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, John W. Myers, Julia M. Greene, John S. Berry, Jonathan Martin, John C. Elkas, Thomas P. Conrads, Kathleen M. Darcy, Chad A. Hamilton, George L. Maxwel, George E. Peoples
Published 2019-08-01